11/21
03:09 am
bgne
BeiGene, Ltd. (NASDAQ: BGNE) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/19
06:00 am
bgne
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
Low
Report
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
11/14
06:00 am
bgne
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
Low
Report
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
11/14
12:02 am
bgne
BeiGene, Ltd. (NASDAQ: BGNE) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/13
01:46 pm
bgne
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
11/13
12:22 am
bgne
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight [Yahoo! Finance]
Low
Report
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight [Yahoo! Finance]
11/12
06:00 am
bgne
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
Low
Report
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
11/6
06:01 am
bgne
BeiGene to Present at the Jefferies London Healthcare Conference
Low
Report
BeiGene to Present at the Jefferies London Healthcare Conference
11/5
09:10 am
bgne
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 [Yahoo! Finance]
Low
Report
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 [Yahoo! Finance]
11/5
09:05 am
bgne
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
Low
Report
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
10/28
06:00 am
bgne
BeiGene Mourns Death of Beloved Board Member Donald Glazer
Low
Report
BeiGene Mourns Death of Beloved Board Member Donald Glazer
10/22
01:40 pm
bgne
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $200.00 to $235.00. They now have an "overweight" rating on the stock.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $200.00 to $235.00. They now have an "overweight" rating on the stock.
10/21
06:00 am
bgne
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
Low
Report
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
10/17
03:46 pm
bgne
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years [Yahoo! Finance]
Low
Report
Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years [Yahoo! Finance]
10/16
06:00 am
bgne
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
Low
Report
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
10/10
10:18 am
bgne
Here's Why BeiGene, Ltd. (BGNE) Rallied in Q3 [Yahoo! Finance]
Low
Report
Here's Why BeiGene, Ltd. (BGNE) Rallied in Q3 [Yahoo! Finance]
9/26
06:21 pm
bgne
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
Low
Report
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
9/26
06:00 am
bgne
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
Low
Report
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
9/18
08:05 am
bgne
BeiGene, Ltd. (NASDAQ: BGNE) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $288.00 price target on the stock.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $288.00 price target on the stock.
9/17
07:00 am
bgne
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
Low
Report
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
9/12
09:03 pm
bgne
BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk [Yahoo! Finance]
Low
Report
BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk [Yahoo! Finance]
9/12
09:00 pm
bgne
BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk
Low
Report
BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk
9/9
07:00 am
bgne
BeiGene Announces Updates to Commercial Leadership Team
Low
Report
BeiGene Announces Updates to Commercial Leadership Team
9/9
01:00 am
bgne
BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
Low
Report
BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
8/28
06:01 am
bgne
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Low
Report
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference